Brainsway vs Lensar
BWAY and LNSR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BWAY and LNSR compare
Brainsway grew revenue faster over the last twelve months (27.3% versus 3.3% for Lensar).
Lensar scores higher on the StockData Score (7 against 5 for Brainsway), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BWAY | LNSR |
|---|---|---|
| Size and price | ||
| Market cap | – | $65.0M |
| Share price | $10.11 | $5.29 |
| Change, 1 year | 28.1% | −48.4% |
| Change, 5 years | 155% | −24.6% |
| Beta (5Y) | – | 1.50 |
| Employees | 129 | 150 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.1× |
| P/B | – | 4.4× |
| Fair value | – | $6.28 |
| Margin of safety | – | 15.8% |
| Growth | ||
| Revenue growth (TTM) | 27.3% (better) | 3.3% |
| Revenue growth, 5Y average | 18.8% (better) | 17.2% |
| EPS growth (TTM) | 260% | – |
| Profitability | ||
| Gross margin | 75.4% (better) | 48.3% |
| Operating margin | 8.3% (better) | −13.5% |
| Net margin | – | 57.6% |
| Financial health | ||
| Debt / equity | – | 0.25 |
| Interest coverage | 2.0× | – |
| Current ratio | 3.59 (better) | 2.39 |
| Altman Z-score | – | −0.86 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 29.2% | 36.0% |
| Held by insiders | 25.5% | – |
Go deeper
- BWAY stock overview
- BWAY income statement
- BWAY valuation and score
- LNSR stock overview
- LNSR income statement
- LNSR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.